Robert Paul Myers

Robert Paul Myers's AcademicInfluence.com Rankings

Robert Paul Myers

Philosophy

#8752

Historical Rank

Logic

#4149

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Robert Paul Myers's Degrees

Doctorate Medicine Stanford University
PhD Biomedical Sciences Stanford University

Why Is Robert Paul Myers Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert Paul Myers's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Compassionate Use of Remdesivir for Patients with Severe Covid-19 (2020) (2312)
Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. (1994) (669)
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. (2017) (603)
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. (2009) (559)
Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. (2013) (538)
Migration and granulomatous reaction after periurethral injection of polytef (Teflon). (1984) (517)
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm (2014) (477)
Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value (2012) (455)
Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients (2012) (452)
A comparison of fibrosis progression in chronic liver diseases. (2003) (447)
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial (2017) (405)
A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. (2010) (403)
FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy (2007) (393)
Diagnostic accuracy of the aspartate aminotransferase‐to‐platelet ratio index for the prediction of hepatitis C–related fibrosis: A systematic review (2007) (391)
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C (2004) (379)
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis (2010) (372)
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. (2003) (352)
Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement (2016) (331)
Historical epidemiology of hepatitis C virus (HCV) in selected countries (2014) (295)
Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study) (2003) (294)
Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot‐assisted techniques (2009) (276)
Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. (2015) (268)
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin (2003) (266)
A Population-Based Study of Pyogenic Liver Abscesses in the United States: Incidence, Mortality, and Temporal Trends (2010) (240)
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways (2015) (233)
Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis (2015) (233)
Fatigue in patients with chronic hepatitis C (2002) (228)
Incidence of primary sclerosing cholangitis: A systematic review and meta‐analysis (2011) (222)
Utilization rates, complications and costs of percutaneous liver biopsy: a population‐based study including 4275 biopsies (2008) (220)
Strategies to manage hepatitis C virus (HCV) disease burden (2014) (218)
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients (2003) (214)
Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials. (2020) (214)
Correlation of margin status and extraprostatic extension with progression of prostate carcinoma (1999) (213)
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. (2007) (213)
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. (2018) (208)
Neurolytic Celiac Plexus Block for Pain Control in Unresectable Pancreatic Cancer (2007) (207)
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open‐label study (2011) (206)
Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis (2010) (202)
Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. (2000) (199)
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. (2018) (199)
Prostate shape, external striated urethral sphincter and radical prostatectomy: the apical dissection. (1987) (198)
Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. (1994) (197)
Cardiac hepatopathy: Clinical, hemodynamic, and histologic characteristics and correlations (2003) (195)
A Critical Analysis of the Current Knowledge of Surgical Anatomy of the Prostate Related to Optimisation of Cancer Control and Preservation of Continence and Erection in Candidates for Radical Prostatectomy: An Update. (2016) (193)
Thrombolytic therapy of pulmonary embolism: a meta-analysis. (2002) (190)
The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. (1995) (183)
Gallbladder polyps: epidemiology, natural history and management. (2002) (181)
Cirrhotic cardiomyopathy and liver transplantation (2000) (180)
Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. (1988) (171)
Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. (2002) (170)
Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. (1996) (168)
The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. (2004) (165)
Epidemiology of gallstones. (2010) (165)
A Model to Identify Sarcopenia in Patients With Cirrhosis. (2016) (161)
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials (2019) (158)
Progression of liver fibrosis in women infected with hepatitis C: Long‐term benefit of estrogen exposure (2004) (154)
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials (2019) (150)
Male urethral sphincteric anatomy and radical prostatectomy. (1991) (146)
Weekend versus weekday admission and mortality from gastrointestinal hemorrhage caused by peptic ulcer disease. (2009) (145)
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial (2020) (145)
Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. (2012) (143)
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. (2012) (143)
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis (2019) (140)
Acetyl‐CoA Carboxylase Inhibitor GS‐0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis (2018) (135)
Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. (2013) (133)
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. (2019) (132)
Staging of prostate cancer. (1994) (130)
Practical surgical anatomy for radical prostatectomy. (2001) (129)
Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy. (2000) (128)
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. (2012) (125)
Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. (2006) (124)
Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. (1983) (123)
The outcomes of pregnancy in patients with cirrhosis: a population‐based study (2010) (122)
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease (2002) (122)
Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: A population‐based study (2009) (121)
Burden of disease and cost of chronic hepatitis C virus infection in Canada (2014) (119)
Acute interstitial nephritis due to omeprazole (2001) (119)
Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. (2005) (117)
Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. (1990) (111)
The definition and preoperative prediction of clinically insignificant prostate cancer. (1996) (109)
Anatomy of radical prostatectomy as defined by magnetic resonance imaging. (1998) (107)
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH (2020) (107)
Noninvasive prediction of fibrosis in patients with chronic hepatitis C (2003) (105)
Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. (1993) (103)
Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. (1989) (103)
Biochemical Markers of Fibrosis in Patients with Chronic Hepatitis C: A Comparison with Prothrombin Time, Platelet Count, and Age–Platelet Index (2004) (102)
Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen (2001) (102)
Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy (2010) (101)
Liver Stiffness by Transient Elastography Predicts Liver-Related Complications and Mortality in Patients with Chronic Liver Disease (2014) (98)
Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. (2002) (95)
B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid (2013) (95)
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C (2002) (95)
Fontan-associated liver disease: Implications for heart transplantation. (2016) (92)
Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. (2011) (92)
Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. (1994) (92)
Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation) (1991) (90)
TWO YEAR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AND ADEFOVIR DIPIVOXIL (ADV) SWITCH DATA IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102), PRELIMINARY ANALYSIS (2008) (88)
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease (2019) (88)
Efficacy of first-generation Cavermap to verify location and function of cavernous nerves during radical prostatectomy: a multi-institutional evaluation by experienced surgeons. (2001) (88)
Perineural Invasion and MIB-1 Positivity in Addition to Gleason Score Are Significant Preoperative Predictors of Progression After Radical Retropubic Prostatectomy for Prostate Cancer (2002) (87)
Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. (2008) (87)
Course of localized adenocarcinoma of the prostate treated by radical prostatectomy (1983) (85)
Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. (1993) (85)
Relationship between grade and stage of adenocarcinoma of the prostate and regional pelvic lymph node metastases. (1982) (82)
Predicting in‐hospital mortality in patients with cirrhosis: Results differ across risk adjustment methods (2009) (81)
Detrusor apron, associated vascular plexus, and avascular plane: relevance to radical retropubic prostatectomy--anatomic and surgical commentary. (2002) (81)
Pregnancy outcomes among liver transplant recipients in the United States: A nationwide case‐control analysis (2010) (80)
Interferon for interferon naive patients with chronic hepatitis C. (2002) (77)
Burden of disease and cost of chronic hepatitis C infection in Canada. (2014) (76)
Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes (2012) (74)
Primary realignment of posterior urethral injuries. (1983) (74)
Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib (2018) (73)
Puboperineales: muscular boundaries of the male urogenital hiatus in 3D from magnetic resonance imaging. (2000) (71)
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV‐infected adults: results of a 6‐month open‐label safety trial (2016) (70)
Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. (2010) (70)
The management of chronic viral hepatitis: a Canadian consensus conference 2004. (2004) (69)
Definitive radiation therapy for prostatic carcinoma: Mayo clinic experience. (1980) (69)
Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration. (1996) (68)
Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. (2011) (68)
Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup. (1992) (68)
Improving the exposure of the prostate in radical retropubic prostatectomy: longitudinal bunching of the deep venous plexus. (1989) (67)
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. (2012) (63)
Upper-gastrointestinal bleeding secondary to peptic ulcer disease: incidence and outcomes. (2014) (63)
Validation of ICD-9-CM/ICD-10 coding algorithms for the identification of patients with acetaminophen overdose and hepatotoxicity using administrative data (2007) (63)
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH (2021) (62)
Sarcoidosis and interferon therapy: report of five cases and review of the literature. (2003) (61)
Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. (2006) (61)
The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C (2003) (59)
Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. (2011) (58)
Morbidity and mortality following coronary artery bypass graft surgery in patients with cirrhosis: a population‐based study (2009) (57)
Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy (2003) (57)
Systematic Review and Meta–Analysis of the Diagnostic Accuracy of Fibrosis Marker Panels in Patients with HIV/Hepatitis C Coinfection (2008) (56)
An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. (2015) (56)
The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. (2008) (55)
Morbidity and Mortality Following Colorectal Surgery in Patients With End-Stage Renal Failure: A Population-Based Study (2010) (55)
Interferon for acute hepatitis C. (2001) (54)
Ambient Ozone Concentrations and the Risk of Perforated and Nonperforated Appendicitis: A Multicity Case-Crossover Study (2013) (54)
Revision of MELD to Include Serum Albumin Improves Prediction of Mortality on the Liver Transplant Waiting List (2013) (54)
The effect of weekend versus weekday admission on outcomes of esophageal variceal hemorrhage. (2009) (53)
Postoperative complications following colectomy for ulcerative colitis: A validation study (2012) (53)
Noninvasive diagnosis of nonalcoholic fatty liver disease. (2009) (51)
Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis. (2019) (51)
Biomarkers of liver fibrosis: What lies beneath the receiver operating characteristic curve? (2011) (50)
The cost‐effectiveness of hepatitis A vaccination in patients with chronic hepatitis C (2000) (49)
The feasibility and reliability of transient elastography using Fibroscan®: a practice audit of 2335 examinations. (2014) (48)
Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. (2006) (48)
Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma of prostate with regional lymph node involvement. (1982) (48)
The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration. (1995) (48)
Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer. (1983) (47)
Hospitalizations for acetaminophen overdose: a Canadian population-based study from 1995 to 2004 (2007) (44)
Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement (2018) (43)
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. (2018) (42)
The anterior layer of Denonvilliers' fascia: a common misconception in the laparoscopic prostatectomy literature. (2007) (42)
Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients (2013) (42)
Adenocarcinoma of the prostate involving the lumbosacral plexus: MRI evidence to support direct perineural spread (2010) (42)
Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH (2020) (41)
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. (2002) (39)
A health technology assessment of transient elastography in adult liver disease. (2013) (39)
Predicting in-hospital mortality in patients undergoing complex gastrointestinal surgery: determining the optimal risk adjustment method. (2012) (37)
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey. (2014) (36)
Decreasing mortality from acute biliary diseases that require endoscopic retrograde cholangiopancreatography: a nationwide cohort study. (2014) (36)
Increased optical magnification from 2.5x to 4.3x with technical modification lowers the positive margin rate in open radical retropubic prostatectomy. (2008) (36)
Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001 (2006) (35)
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. (2018) (34)
Elective Resection of Colon Cancer by High-Volume Surgeons Is Associated with Decreased Morbidity and Mortality (2011) (33)
Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients. (2013) (32)
Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma. (1990) (32)
Incidence of stricture following primary realignment of the disrupted proximal urethra. (1972) (32)
Population‐based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis (2007) (32)
Amoebic liver abscess in USA: a population‐based study of incidence, temporal trends and mortality (2011) (32)
The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH). (2020) (31)
Correlation of prostate‐specific acid phosphatase and prostate‐specific antigen immunocytochemistry with survival in prostate carcinoma (1989) (31)
Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers (2017) (30)
Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. (2006) (30)
Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis. (2015) (30)
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. (2019) (30)
Compassionate Use of Remdesivir in Covid-19. Reply. (2020) (29)
Hepatitis C, alcohol abuse, and unintentional overdoses are risk factors for acetaminophen‐related hepatotoxicity (2009) (29)
Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection (2013) (29)
Relationship between hospital volume and outcomes of esophageal variceal bleeding in the United States. (2008) (29)
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. (2022) (29)
Intentional ipecac poisoning in children. (1988) (28)
Validation of the five‐variable Model for End‐stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list (2014) (28)
Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. (2000) (28)
The Impact of Follow-Up Educational Telephone Calls on Patients after Radical Prostatectomy: Finding Value in Low-Margin Activities (2011) (28)
Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease (2017) (27)
Inflammatory bowel disease patients who leave hospital against medical advice: Predictors and temporal trends (2009) (26)
Making anatomic terminology of the prostate and contiguous structures clinically useful: Historical review and suggestions for revision in the 21st Century (2009) (26)
A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation (2021) (25)
Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. (2006) (25)
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (2021) (24)
DNA ploidy and surgically treated prostate cancer. Important independent association with prognosis for patients with prostate carcinoma treated by radical prostatectomy (1995) (24)
Validity of administrative data for the diagnosis of primary sclerosing cholangitis: a population‐based study (2011) (24)
Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. (1997) (24)
Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients (2017) (24)
Pharmacoangiographic evidence of the presence and anatomical dominance of accessory pudendal artery(s). (2008) (24)
Characteristics of patients with cirrhosis who are discharged from the hospital against medical advice. (2009) (24)
Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series. (2012) (23)
Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to suppression of hepatic de novo lipogenesis and significant improvements in MRI-PDFF, MRE, and markers of fibrosis after 12 weeks of therapy in patients with NASH (2017) (23)
Epidemiology and trends of cryptococcosis in the United States from 2000 to 2007: A population-based study (2018) (23)
Emergency department visits for acetaminophen overdose: a Canadian population-based epidemiologic study (1997-2002). (2007) (23)
Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. (2001) (23)
Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes (2020) (22)
Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials (2017) (22)
Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO (2018) (21)
Recent Trends of Hepatic Resection in Canada: 1995–2004 (2008) (21)
Structure of the adult prostate from a clinician's standpoint (2000) (21)
A case of valproate-induced hyperammonemic encephalopathy: look beyond the liver (2007) (21)
Subjective and objective comparison of critical care pathways for open donor nephrectomy. (2002) (21)
Validation of coding algorithms for the identification of patients hospitalized for alcoholic hepatitis using administrative data (2015) (20)
The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients (2013) (20)
Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis (2020) (20)
Radical prostatectomy: Making it a better operation in the new millennium (2001) (20)
Reinforced interferon alpha‐2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial (2003) (20)
Validation of coding algorithms for the identification of patients with primary biliary cirrhosis using administrative data. (2010) (20)
Experience with the bowel stapler for ileal conduit urinary diversion. (1982) (19)
Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis. (2013) (19)
Rofecoxib-induced hepatotoxicity: a forgotten complication of the coxibs. (2006) (19)
Feasibility and reliability of the FibroScan S2 (pediatric) probe compared with the M probe for liver stiffness measurement in small adults with chronic liver disease. (2013) (19)
The value of excretory urography as a screening test in asymptomatic patients. (1972) (19)
Urinary tract reconstruction in renal transplantation. Mayo Clinic experience and review of literature. (1980) (19)
Ulcerative colitis-associated hospitalization costs: a population-based study. (2015) (18)
Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C. (2007) (18)
Definitive therapy for prostate carcinoma: Mayo Clinic results at 15 years after treatment. (1994) (18)
Nucleolar grading of prostatic adenocarcinoma: Light microscopic correlation with disease progression (1982) (17)
Re: Francesco Montorsi, Timothy G. Wilson, Raymond C. Rosen, et al. best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena consensus panel. Eur Urol 2012;62;368-81. (2013) (17)
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis (2021) (16)
The Second Canadian Symposium on hepatitis C virus: a call to action. (2013) (16)
Anatomical variation of the superficial preprostatic veins with respect to radical retropubic prostatectomy. (1991) (16)
Cystectomy after radiotherapeutic ablation of invasive transitional cell cancer. (1977) (16)
52 A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis (2006) (16)
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy (2017) (16)
Sertoli cell tumor: case report with ultrastructural findings. (1975) (15)
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (2021) (15)
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. (2020) (14)
Development and validation of method for defining conditions using Chinese electronic medical record (2016) (14)
The management of chronic viral hepatitis: A Canadian consensus conference 2004. (2004) (14)
A198 PHARMACODYNAMIC EFFECTS OF THE ORAL, NON-STEROIDAL FARNESOID X RECEPTOR AGONIST GS-9674 IN HEALTHY VOLUNTEERS (2018) (14)
A quantitative metabolomics profiling approach for the noninvasive assessment of liver histology in patients with chronic hepatitis C (2016) (14)
Disparities in the surgical treatment of colorectal liver metastases. (2013) (14)
Creation and Validation of Patient Specific Anatomical Models for Prostate Surgery Planning Using Virtual Reality (1996) (13)
Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial (2017) (13)
Risk factors for mortality in patients with alcoholic hepatitis and assessment of prognostic models: A population-based study. (2015) (13)
Comparison of risk adjustment methods in patients with liver disease using electronic medical record data (2017) (13)
Noninvasive markers of liver fibrosis: playing the probabilities (2008) (12)
Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C (2001) (12)
A prospective randomized comparison of epidural infusion of fentanyl and intravenous administration of morphine by patient-controlled analgesia after radical retropubic prostatectomy. (1992) (12)
Predictors of Significant Fibrosis in Chronic Hepatitis B Patients With Low Viremia (2013) (11)
Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada (2016) (11)
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis (2018) (11)
Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis (2019) (11)
Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis (2017) (11)
Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). (2011) (11)
The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C (2003) (11)
Pneumococcal vaccination of the elderly during visits to acute care providers: who are vaccinated? (2014) (11)
Re: Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J. S. Jones, A. Patel, L. Schoenfield, J. C. Rabets, C. D. Zippe and C. Magi-Galluzzi. J Urol, 175: 485-488, 2006. (2006) (11)
Serum biochemical markers of liver fibrosis in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected patients (2002) (11)
Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations from the Multi-stakeholder Liver Forum. (2020) (10)
Long-Term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients with Chronic HCV Infection. (2020) (10)
Management of chronic hepatitis C in French departments of internal medicine and infectious diseases (2005) (10)
Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH (2018) (10)
NNRTI‐related or ‐unrelated hepatotoxicity? (2002) (10)
Adenocarcinoma of the prostate involving 2 cell types (prostate specific antigen producing and carcinoembryonic antigen producing) with selective metastatic spread. (1991) (10)
Anatomic considerations in radical prostatectomy (2008) (9)
A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis (2020) (9)
Predictors of mortality among patients undergoing colectomy for ischemic colitis: A population-based United States study. (2014) (9)
Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study. (2015) (9)
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. (2022) (9)
The effects of patient cost sharing on inpatient utilization, cost, and outcome (2017) (9)
SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis (2019) (8)
Hospital performance reports based on severity adjusted mortality rates in patients with cirrhosis depend on the method of risk adjustment . (2012) (8)
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. (2022) (8)
Radical prostatectomy for high-risk prostate cancer. (2010) (7)
The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. (2019) (7)
Bladder involvement in hereditary angioedema. (1980) (7)
[124] 76 WEEK FOLLOW UP OF HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH TELBIVUDINE, ADEFOVIR OR SWITCHED FROM ADEFOVIR TO TELBIVUDINE (2007) (7)
En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH (2022) (7)
Prostate cancer--neurovascular preservation; smoking cessation may enhance prognosis? (1995) (7)
Meta-analysis of transarterial embolization in patients with unresectable hepatocellular carcinoma. (2003) (7)
Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C. (2000) (7)
Longitudinal changes in liver stiffness by magnetic resonance elastography (MRE), liver fibrosis, and serum markers of fibrosis in a multi-center clinical trial in nonalcoholic steatohepatitis (NASH) (2017) (7)
A179 FEATURES OF THE METABOLIC SYNDROME ARE ASSOCIATED WITH LACK OF SERUM ALT NORMALIZATION DURING THERAPY FOR CHRONIC HEPATITIS B (2018) (6)
341 PERFORMANCE OF THE FIBROSCAN XL PROBE FOR LIVER STIFFNESS MEASUREMENT IN OBESE PATIENTS: A MULTICENTER VALIDATION STUDY (2011) (6)
Penile gangrene successfully treated by débridement and scrotal skin bridge: case report. (1973) (6)
Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy. (2006) (6)
The radial distance of extraprostatic extension of prostatic adenocarcinoma: Implications for prostate brachytherapy (1998) (6)
Adenomatous polyp in defunctionalized colonic segment used as a urinary bladder. (1988) (6)
Neurofibromatosis presenting as perineal pain and urethral burning. (1989) (6)
Surgical planning for radical prostatectomies using three-dimensional visualization and a virtual reality display system (1995) (6)
Serum LYSYL Oxidase-Like-2 (SLOXL2) Levels Correlate with Disease Severity in Patients with Primary Sclerosing Cholangitis (2016) (5)
Pharmacokinetics of selonsertib, GS-9674, and/or GS-0976 in combination in healthy subjects (2017) (5)
Survival after hepatic resection: impact of surgeon training on long-term outcome. (2013) (5)
THE TREATMENT OF PULMONARY TUBERCULOSIS WITH SULFAPYRIDINE (1939) (5)
Impact of pharmaceutical industry versus university sponsorship on survey response: a randomized trial among Canadian hepatitis C care providers. (2007) (5)
Infections with Multiple Hepatotropic Viruses (2002) (5)
Localised Prostate Cancer: Important Points of Conduct for Radical Retropubic Prostatectomy (2002) (5)
Prospective validation of the Enhanced Liver Fibrosis test for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (2017) (5)
Radical Retropubic Prostatectomy: Balance between Preserving Urinary Continence and Achievement of Negative Margins (1995) (5)
Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis (2017) (5)
Hepato‐biliary clinical trials and their inclusion in the Cochrane Hepato‐Biliary Group register and reviews (2011) (4)
Accuracy of Administrative Data in Identifying Ulcerative Colitis Patients Presenting with Acute Flare and Undergoing Colectomy: 2010 Presidential Poster: 1270 (2010) (4)
Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat (2020) (4)
Hospital stays for hepatitis B or C virus infection or primary liver cancer among immigrants: a census-linked population-based cohort study. (2016) (4)
[508] IN HEPATITIS B PATIENTS TREATED WITH EITHER ADEFOVIR OR TELBIVUDINE, MAXIMAL EARLY HBV SUPPRESSION AT 24 WEEKS PREDICTS OPTIMAL ONE-YEAR EFFICACY (2007) (4)
1287 RITUXIMAB FOR REFRACTORY AUTOIMMUNE HEPATITIS: F RESULTS OF A PHASE 1 STUDY (2011) (4)
Racial disparities in the management of hospitalized patients with cirrhosis and portal hypertension (2007) (4)
Fascias of the male external genitalia and perineum (1994) (4)
Re: Antegrade approach to radical retropubic prostatectomy in patients with difficult apical dissection. (1992) (4)
Radical Prostatectomy and the Influence of Early Endocrine Therapy for Stage D1 Prostate Cancer: Long-Term Follow-Up Study (1988) (4)
Prognostic value of flow cytometric nuclear DNA analysis in stage C prostate carcinoma (1988) (4)
Multiple focal nodular hyperplasia and steatosis: Atypical imaging characteristics. (2001) (3)
Perfusion monitoring during radical perineal prostatectomy. (1997) (3)
1011 RISK AND PREDICTORS OF MORTALITY OR HEPATOCELLULAR CARCINOMA AMONG ENTECAVIR- OR ADEFOVIR-TREATED CHRONIC HEPATITIS B PATIENTS WITH EVIDENCE OF HEPATIC DECOMPENSATION (2010) (3)
Immunologic complications of the hepatitis C virus (2007) (3)
Fatal hepatic decompensation in a patient with hepatitis B cirrhosis following famciclovir withdrawal. (2000) (3)
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis (2022) (3)
Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests (2015) (3)
Automated CNN-Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Inter-method Agreement and Fibrosis Stage Discriminative Performance. (2022) (3)
Su1522 - Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH (2018) (3)
LIVER STIFFNESS MEASUREMENT BY TRANSIENT ELASTOGRAPHY FOR THE PREDICTION OF FIBROSIS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS IN A RANDOMIZED TRIAL OF SIMTUZUMAB (2016) (3)
Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic Whites in the STELLAR trials. (2022) (3)
Preliminary efficacy and safety of acetyl-CoA carboxylase inhibitor GS-0976 in patients with compensated cirrhosis due to NASH (2018) (3)
Migration and Granulomatous Reaction After Periurethral Injection of Polytef (Teflon) (1985) (3)
Polytef (Teflon) migration after periurethral injection: tracer and x-ray microanalysis techniques in experimental study. (1984) (3)
Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients (2015) (3)
Lessons learned from liver transplantation with the Canadian First Nations. (2011) (3)
Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis. (2022) (2)
PS-016-Prospective evaluation of serum alkaline phosphatase variability and prognostic utility in primary sclerosing cholangitis using controlled clinical trial data (2019) (2)
Hepatitis B awareness and education: a failing grade. (2011) (2)
Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients (2022) (2)
The anatomical radical retropubic prostatectomy step by step (2007) (2)
Lessons learned from liver transplantation with the (2011) (2)
A rare tumour in the mandible of a young man: a case report and literature review of mesenchymal chondrosarcoma of the mandible (2009) (2)
Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring (2020) (2)
Weekend Versus Weekday Admission and Mortality from Gastrointestinal Hemorrhage Due to Peptic Ulcer Disease.: 1013 (2008) (2)
Feulgen-stained histologic sections of prostate needle biopsy specimens: Reliability of DNA static image cytometry (1996) (2)
Evaluation of SOMAscan as a discovery platform to identify noninvasive protein biomarkers for diagnosis and monitoring of NASH (2018) (2)
Treatment with selonsertib, an inhibitor of apoptosis signal-regulating kinase 1, hepatic phospho-p38 expression and markers of hepatocellular apoptosis and necrosis in patients with nonalcoholic steatohepatitis (2017) (2)
Fifth Joint Meeting of the American Urological Association and the Japanese Urological Association International Affiliate Society Meeting at the 105th Annual Meeting of the American Urological Association (2010) (2)
Validation of serum fibrosis marker panels in patients with primary sclerosing cholangitis (PSC) in a randomized trial of simtuzumab (2015) (2)
Results of salvage radiation therapy for a rising serum prostate specific antigen level following radical prostatectomy for prostate cancer (2004) (2)
Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (2017) (2)
Cryptorchidism reassessed. Is there an optimal time for surgical correction? (1973) (2)
Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC. (2022) (2)
Correlations between Hepatic Morphometric Collagen Content, Histologic Fibrosis Stage, and Serum Markers in Patients with Primary Sclerosing Cholangitis (PSC) (2016) (2)
Anatomy: Anatomic Considerations for Efficiency and Precision in Robotic-Assisted Radical Prostatectomy (2013) (1)
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH (2022) (1)
Correlation between the Hepatic Venous Pressure Gradient and Alpha-Smooth Muscle Actin (SMA) Expression in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (2016) (1)
Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials (2019) (1)
The Whole Life Prostate Book: Everything that Every Man—at Every Age—Needs to Know About Maintaining Optimal Prostate Health, H.B. Carter, G.S. Couzens. Free Press, New York (2012), 496 pages (2012) (1)
Whither go pro-erectile nerves of the neurovascular bundles? (2011) (1)
Cost‐effectiveness of hepatitis A vaccination in patients with chronic hepatitis C (2000) (1)
SAT-269-The sustained deleterious impact of viremia on patient reported outcomes in patients with chronic hepatitis C who don’t achieve sustained virologic response (2019) (1)
Prospective validation of serum alkaline phosphatase for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (2017) (1)
IDDF2019-ABS-0133 Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib (2019) (1)
FRI-016-Validation of the PREsTo machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis (2019) (1)
Characterization of changes in lipoprotein profiles of patients with nonalcoholic steatohepatitis treated with the acetyl-CoA carboxylase inhibitor GS-0976 (2018) (1)
Corrigendum to “Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C” [J Hepatol 36 (2002) 812–818] (2002) (1)
1403: “Insignificant” Prostate Cancer Treated by Radical Retropubic Prostatectomy has a Risk of Progression Similar to Low-Risk “Significant” Cancer (2007) (1)
IDDF2019-ABS-0131 Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials (2019) (1)
Re: RP Myers, H Shah, KW Burak, et al. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 2015;29(1):19-34. (2015) (1)
Prediction of fibrosis improvement in patients with advanced fibrosis due to NASH using a machine learning approach: Unravelling the placebo response (2018) (1)
Exploring the Impact of Health Insurance on Health Care Utilization and Outcome Using Electronic Medical Record Data (2017) (1)
Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis phenotypes in patients with primary sclerosing cholangitis (2017) (1)
Temporal trends in the use of diagnostic imaging for inpatients with pancreatic conditions: How much ionizing radiation are we using? (2016) (1)
Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis (2022) (1)
The association of circulating microRNAs (miRs) with liver fibrosis stage and the impact of selonsertib treatment in patients with NASH (2018) (1)
Hospitalizations for Upper Gastrointestinal Bleeding Secondary to Peptic Ulcer Disease: A Population-Based Validation and Epidemiological Study (2011) (1)
Su1521 - Preliminary Efficacy and Safety of Acetyl-Coa Carboxylase (ACC) Inhibitor GS-0976 in Patents with Compensated Cirrhosis due to NASH (2018) (1)
Developing and Validating Electronic Medical Record Based Case Definitions for Liver Diseases and Comorbidities (2017) (1)
Tu2000 Incidence and Mortality of Ischemic Colitis: A Population-Based Study (2013) (1)
[What are the indications for treatment of acute hepatitis C?]. (2002) (1)
950: Pre-Operative PSA Doubling Time is More Powerful than PSA or PSA Velocity as a Predictor of Post Radical Prostatectomy Outcomes (2005) (1)
Impact of hepatic steatosis and controlled attenuation parameter (CAP) on accuracy of fibrosis staging using transient elastography (2017) (1)
Hepatic Proton Density Fat Fraction Correlates with Histologic Measures of Steatosis and is Responsive to Change in those Measures in a Multi-Center Nonalcoholic Steatohepatitis Clinical Trial (2017) (1)
Pay now or pay (more) later: tracking the costs of hepatitis C infection. (2010) (1)
Correction: The effects of patient cost sharing on inpatient utilization, cost, and outcome (2018) (1)
Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. (2021) (1)
Possible new clinical sign of hyperammonemia (2007) (1)
Validation, current use and future directions of the Model for End-stage Liver Disease for liver transplant allocation in Canada. (2015) (1)
Evaluation of cytochrome P450- and transporter-mediated drug-drug interactions with the farnesoid x receptor agonist GS-9674 and phenotypic probe substrates and inhibitors/inducers (2017) (1)
271: Age at Treatment is not a Good Predictor of Outcome Following Radical Retropubic Prostatectomy (2005) (0)
Validity of Administrative Data for the Diagnosis of Primary Sclerosing Cholangitis: A Population-Based Study: 182 (2010) (0)
Patient CareEditorial Commentary (2014) (0)
Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum Levels of Lysyl Oxidase-Like-2 (Loxl2) (2016) (0)
Sa1521 Mortality From Acute Pancreaticobiliary Diseases Requiring Endoscopic Retrograde Cholangiopancreatography (ERCP) Has Decreased Over Time (2013) (0)
M1620 Increased Rate of Sphincter Preservation Following Rectal Cancer Resection in High Volume Hospitals (2010) (0)
302 THE RELATIONSHIP BETWEEN HOSPITAL VOLUME AND OUTCOMES OF ESOPHAGEAL VARICEAL BLEEDING (2008) (0)
PS-086-Sustained virologic response in patients with cirrhosis from chronic hepatitis C leads to sustained and long-term improvement of health-related quality of life, fatigue, and work productivity (2019) (0)
PS-012-Validation of histologic and non-invasive measures of fibrosis as surrogate end points of disease progression in patients with primary sclerosing cholangitis (2019) (0)
1449-P: The Enhanced Liver Fibrosis (ELF) Score Predicts Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH) (2020) (0)
524 POTENTIAL SURVIVAL BENEFIT OF THE 5-VARIABLE MODEL FOR END-STAGE LIVER DISEASE (5VMELD) FOR LIVER TRANSPLANT ALLOCATION (2011) (0)
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis (2023) (0)
Investigating the relationship between rare genetic variants and advanced fibrosis in pediatric nonalcoholic fatty liver disease (2018) (0)
1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH) (2019) (0)
Predicting Postoperative Mortality from Comorbidity Indices in Administrative Databases Among Inflammatory Bowel Disease Patients: 1142 (2008) (0)
Hepatology Noninvasive diagnosis of nonalcoholic fatty liver disease (2009) (0)
University of Birmingham Ulcerative colitis-associated hospitalization costs (2016) (0)
The Prostate (Butterworths International Medical Reviews, Urology, Vol 3) (1986) (0)
SAT-315-Clinical utility and application of non-invasive tests of fibrosis in the selection of patients with advanced fibrosis due to NASH in the Phase 2 ATLAS trial (2019) (0)
Mo1029 Variceal Screening With Unsedated THIN Scope Endoscopy Is Cost-Effective in Patients With Child-Pugh a Cirrhosis (2013) (0)
OPTIMAL OUTCOME PREDICTION AFTER RADICAL PROSTATECTOMY (1999) (0)
Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis with Telbivudine or Adefovir (2020) (0)
Paper alert. (2020) (0)
Open Radical Prostatectomy: How Can Intra-Operative, Peri-Operative and Post-Operative Complications be Prevented? (2008) (0)
264 - Total Bladder Replacement with Detubularized Right Colon (1987) (0)
Pachydermatocele of Left Labium (1876) (0)
764 – Protein and Mirna Profiling of Circulating Extracellular Vesicles in Patients with Primary Sclerosing Cholangitis (2019) (0)
Prospective Validation of the Enhanced Liver Fibrosis (ELF) Test for the Prediction of Disease Progression in a Randomized Trial of Patients with Primary Sclerosing Cholangitis (PSC) (2017) (0)
SAT-283-Plasma acylcarnitines are biomarkers of magnetic resonance imaging-proton density fat fraction response in NASH patients treated with the ACC inhibitor GS-0976 (2019) (0)
The Potential Role of Fatigue in Identifying Patients with NASH and Advanced Fibrosis who Experience Disease Progression. (2022) (0)
100 Feasibility and reliability of the FibroScan S 2 ( pediatric ) probe compared with the M probe for liver stiffness measurement in small adults with chronic liver disease (2012) (0)
NAFLD and NASH : Clinical II Monday , Nov 12 8 : 00 AM NashTest 2 , a new (0)
Phenome-wide association study of the FIB-4 index in a large, populational-based study in the United States (2020) (0)
Reply to HEP-20-0140 Letter to the Editors: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment? (2020) (0)
1400 DISCOVERY OF A DIRECT ASSOCIATION BETWEEN PRIMARY BILIARY CIRRHOSIS AND LOW BONE MASS: IDENTIFICATION OF TNFSF11/RANKL AS A RISK LOCUS FOR PATIENTS WITH PBC (2012) (0)
Reply (2012) (0)
the Impact of Waiting for Emergent Endoscopic Procedures On Mortality and Resource Utilization in Patients with Gastrointestinal Disorders (2009) (0)
Prostate Specific Antigen Half-Life Following Salvage Radiation Therapy for an Isolated PSA Elevation After Radical Prostatectomy (2005) (0)
Re: Radical Surgery for Advanced Prostate by, W. J. Catalona, J. Urol., 147: 916, 1992 (1993) (0)
52 INCREASED MORTALITY ON THE LIVER TRANSPLANT WAITING LIST IN FEMALES UNDER THE MELD ALLOCATION SYSTEM: UTILITY OF REVISED MELD INCORPORATING ESTIMATED GLOMERULAR FILTRATION RATE (2010) (0)
Benign Prostatic Hypertrophy (1984) (0)
1948: Saturation Biopsy: Does it Really Detect More Cancer? (2007) (0)
SAT-273-Impact of age on routinely available non-invasive tests for the discrimination of advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib (2019) (0)
Su1541 - Responsiveness of Controlled Attenuation Parameter (CAP) and Its Correlation with Magnetic Resonance Imagingproton Density Fat Fraction (MRI-PDFF) in a Multi-Center Clinical Trial of Subjects with Nonacoholic Steatohepatitis (NASH) (2018) (0)
Book ReviewsEndourologyC.C. Carson, N.R. Dunnick, Churchill Livingstone, New York (1985), p. 331 (1987) (0)
Is the location of a positive surgical margin after radical prostatectomy important for prognosis? (2008) (0)
954 – Chronic Hepatitis C (CHC) Patients Who Do Not Achieve Sustained Virologic Response (SVR) Experience Worsening of Their Health-Related Quality of Life (HRQL) (2019) (0)
THU-024-Methylation signatures in blood show accelerated epigenetic aging in patients with primary sclerosing cholangitis compared to healthy controls (2019) (0)
Reply to HEP-20-0871 Letter to the Editors: Cilofexor in patients with non-alcoholic steatohepatitis (NASH): Is it really effective? (2020) (0)
M1621 Elective Resection of Colon Cancer is Associated With Decreased Morbidity and Mortality in High-Volume Surgeons (2010) (0)
Whole exome sequencing identifies rare nonsense mutations enriched among patients with advanced fibrosis due to nonalcoholic steatohepatitis (2018) (0)
Adenocarcinoma of the Prostate (Clinical Practice in Urology series) (1988) (0)
P368 COGNITIVE AND EMOTIONAL PROCESSING NETWORKS ARE IMPACTED BY SENSORY INPUT TO THE THALAMUS IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS (2014) (0)
AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trials (2023) (0)
NON-INVASIVE TESTS FOR FIBROSIS IN FONTAN-ASSOCIATED LIVER DISEASE ARE CONFOUNDED BY CONGESTION (2014) (0)
Responsiveness of controlled attenuation parameter (CAP) and its correlation with magnetic resonance imaging-proton density fat fraction (MRI-PDFF) in a multi-center clinical trial of subjects with nonalcoholic steatohepatitis (NASH) (2018) (0)
Experience With the Bowel Stapler for Ileal Conduit Urinary Diversion (1983) (0)
Carcinoma of the Bladder John G. Connolly, Ed. Progress in Cancer Research and Therapy, Volume 18, New York, Raven Press, 1981, 292 pp, $32.00 (1982) (0)
University of Birmingham Predictors of mortality among patients undergoing colectomy for ischemic colitis (2016) (0)
Thrombolytic therapy of pulmonary embolism. (1968) (0)
Physicians' perception of utility in Crohn's disease (1998) (0)
Tu1109 The Global Incidence of Appendicitis: A Population-Based North American Cohort Study and Systematic Review (2015) (0)
Serum fibroblast growth factor 19, 7α-Hydroxy-4-Cholesten-3-one, and bile acids and their associations with clinical characteristics in primary sclerosing cholangitis (2017) (0)
Re: Radical surgery for advanced prostate cancer and for radiation failures. (1993) (0)
SAT-151-What are the predictors of impairment of patient-reported outcome in non-alcoholic steatohepatitis? (2019) (0)
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B (2003) (0)
Validation of a quantitative imaging assessment biomarker metric for MRI-estimated proton density fat fraction in a large multi-center clinical trial (2018) (0)
Reply: (2012) (0)
1850-P: High Prevalence of Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH): The Impact on Patient-Reported Outcomes (PROs) (2020) (0)
Sa1015 Outpatient Thin Scope Endoscopy (TSE) for Variceal Screening in Child's a Cirrhotics: A Single Centre Satisfaction Assessment (2012) (0)
Accurate prediction of clinical disease progression in patients with advanced fibrosis due to NASH using a Bayesian machine learning approach (2018) (0)
Mo1942 The Feasability and Reliability of Transient Elastography by FibroScan: A Practice Audit of 3,000 Examinations (2012) (0)
91 MORBIDITY AND MORTALITY FOLLOWING CORONARY ARTERY BYPASS GRAFT (CABG) SURGERY IN PATIENTS WITH CIRRHOSIS: A POPULATION-BASED STUDY (2008) (0)
Genome-Wide Association Study of Clinically Significant Portal Hypertension in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis (2016) (0)
PNPLA3 Variants Confer an Increased Risk of Advanced Fibrosis Due to Non-Alcoholic Steatohepatitis (2016) (0)
THU-348-Patients with non-alcoholic steatohepatitis experience severe impairment of health related quality of life (2019) (0)
9 The Relationship Between Hospital Volume and Outcomes of Esophageal Variceal Bleeding (2008) (0)
Serum bile acids are markedly elevated in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH) (2018) (0)
Letter: lipid‐lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B—more evidence is needed. Authors’ reply (2017) (0)
830: PSA Doubling Time is an Important Predictor of Outcome in Patients with Hormone Refractory Recurrence following Prostatectomy (2005) (0)
[559] NONINVASIVE ASSESSMENT OF FIBROSIS IN PATIENTS WITH CHRONIC HCV: A SYSTEMATIC REVIEW OF FIBROTEST (FT) AND FIBROSCAN® (FS) (2007) (0)
525 EARLY CLINICAL AND ECONOMIC OUTCOMES OF LIVING LIVER DONORS IN THE UNITED STATES: A POPULATION-BASED STUDY (2011) (0)
Ureteral guide to aid in spatulation of ureter and placement of sutures for uretero-intestinal anastomosis. (1971) (0)
Incidence of stricture following primary realignment of the disrupted proximal urethra. (1972) (0)
Reply: (2008) (0)
Novel characterization of the gut microbiome in patients with NASH and longitudinal changes associated with histological improvement (2018) (0)
Unsedated Peroral Thin Scope Endoscopy for Screening of Esophageal Varices in Endoscopy-Naïve Child-Pugh A Cirrhotics: 487 (2014) (0)
Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate (2023) (0)
Health-related quality of life in Crohn's disease: Whose preferences should we use? (2000) (0)
646: 25-Year Outcomes of Radical Prostatectomy for the Treatment of All Stages of Non-Metastatic Prostate Cancer (2006) (0)
V322: Advancement in Open Radical Retropubic Prostatectomy: Increased Optical Magnification Lowers Positive Margin Rate (2006) (0)
Clinical prediction rule to determine the need for repeat ERCP after endoscopic treatment of postsurgical bile leaks. (2017) (0)
Methylation signatures in blood show accelerated epigenetic aging in patients with non-alcoholic steatohepatitis compared to healthy controls (2017) (0)
1587: Primary Gleason Grade 4 Prostate Cancer Treated by Radical Prostatectomy: Pathological Stage, DNA Ploidy and Tumor Size are Stronger Determinants of Survival than Secondary Gleason Grade (2006) (0)
Reply from Authors re: William D. Steers. Remarks about Remarkable Surgical Outcomes. Eur Urol. 2012;61:885–6 (2012) (0)
Palmitate breath test : A dynamic marker of fatty acid oxidation in non-alcoholic fatty liver disease (2017) (0)
Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (PSC) (2018) (0)
Comparison of Risk Adjustment Methods in Patients with Liver Disease Using Electronic Medical Record (2017) (0)
472: Predictors of Biochemical Relapse Following Salvage Radiation Therapy for Recurrent Prostate Cancer (2005) (0)
Epidemiology and outcomes of primary biliary cirrhosis in the Calgary Health Region: A population-based study (2008) (0)
On Foot Mat Use. (2017) (0)
The correlation between PSA and prostate cancer volume is not influenced by the serum testosterone concentration (1994) (0)
Defining Clinically Insignificant Prostate Cancer-Reply (1996) (0)
Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH (2023) (0)
The Medical Management of Prostate Cancer (European School of Oncology Monographs) (1988) (0)
1463: Cancer Characteristics in Men Diagnosed with Prostate Cancer Subsequent to Initial Biopsy Showing High Grade Prostatic Intraepithelial Neoplasia (2005) (0)
Pegylated interferon for acute hepatitis C (2007) (0)
Congenital diverticulum of the renal pelvis: report of a case. (1972) (0)
The conundrum of cryptogenic liver disease with advanced fibrosis: Poor clinical outcomes without treatment options (2018) (0)
Sa1570 Sex-Specific Differences in Patients With Primary Sclerosing Cholangitis (2016) (0)
The assessment of liver fibrosis stage by two-dimensional shear wave ultrasound and Transient Elastography in patients with chronic liver disease (2017) (0)
Comparing the ECG and the fourth heart sound for detecting acute MI (2004) (0)
Mechanism for hypertriglyceridemia and effect of fibrate coadministration during acetyl-CoA carboxylase inhibitor treatment (2018) (0)
SAT-331-Use of machine learning to predict diagnosis codes for non-alcoholic steatohepatitis in administrative healthcare data (2019) (0)
Reply (2020) (0)
M1757 Predictors of Mortality Due to Pyogenic Liver Abscesses: An Analysis of US Hospitalizations from 1998 to 2004 (2008) (0)
Reply (2020) (0)
Diagnostic performance of a computerized algorithm for augmenting the ECG with acoustical data (2003) (0)
Tu1565 – Clinical Utility and Application of Noninvasive Tests of Fibrosis in the Selection of Patients with Advanced Fibrosis Due to Nash in the Phase 2 Atlas Trial (2019) (0)
The Need for Repeat Endoscopic Retrograde Cholangiopancreatography in Patients with Biliary Leaks Following Cholecystectomy (2013) (0)
IBD Patients Who Leave Against Medical Advice: Predictors of the Patient Profile (2008) (0)
268: Trends in Gleason Grading of Radical Retropubic Prostatectomy Specimens over Time (2005) (0)
M1897 Risk and Predictors of Mortality or Hepatocellular Carcinoma Among Entecavir- or Adefovir-Treated Chronic Hepatitis B Patients With Evidence of Hepatic Decompensation (2010) (0)
THU-438-The presence of type 2 diabetes is independently associated with impairment of patient-reported outcomes in patients with non-alcoholic steatohepatitis (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert Paul Myers?

Robert Paul Myers is affiliated with the following schools:

University of Western Ontario
University of Calgary